-
Samson Clinical Announces Last Patient Last Visit in its Pivotal Phase III Study of Sublingual Minoxidil for Male Androgenetic Alopecia
MELBOURNE, Australia, May 18, 2026 /PRNewswire/ — Samson Clinical Operations Pty Ltd (Samson) announced completion of the Last Patient Last Visit in its pivotal Phase III clinical trial evaluating low dose sublingual minoxidil in male Androgenetic Alopecia (AGA)(SAM-002). Topline results are expected in Q2 2026. SAM-002 is a 24-week, multicentre, double-blind, placebo-controlled study investigating a
-
Ampa Accelerates Rollout of Portable Neuromodulation Platform for Depression with Oversubscribed Financing
PALO ALTO, Calif., May 14, 2026 /PRNewswire/ — Transcranial magnetic stimulation (TMS) has been an FDA-cleared therapy for treatment-resistant depression since 2008, but the equipment has historically been too expensive, large, and complex for most clinics to offer. Ampa, co-founded by seminal researcher Jonathan Downar, MD, PhD, has developed a new TMS device that costs
-
Health eCooks® Recipe Website Launches New Renal Diet Recipes for People with Kidney Disease
WASHINGTON CROSSING, Pa., May 13, 2026 /PRNewswire/ — Health eCooks®, a heart-healthy recipe website by Baldwin Publishing, is proud to announce the launch of its newest recipe category: Renal Diet Recipes. Designed specifically for the growing population of people managing chronic kidney disease (CKD), the healthy kidney recipes join the website’s robust collections of diabetes, heart-healthy,
-
Cantex and Headlamp Health Forge Strategic Partnership to Accelerate Azeliragon Development via Agentic Precision Neuropsychiatry for Severe Depression and Fatigue in Patients with Multiple Sclerosis
Headlamp’s Lumos AI Platform to Apply Multifactorial Phenotyping to Identify Responder Patient Phenotypes Across a Population Underserved by Current Treatments WESTON, Fla. and SAN FRANCISCO, May 13, 2026 /PRNewswire/ – Cantex Pharmaceuticals, Inc. (“Cantex”), a clinical-stage biopharmaceutical company, and Headlamp Health (“Headlamp”), an AI-native precision neuropsychiatry company, today announced a collaboration to apply Headlamp’s Lumos AI™
-
PM360 Names Momentum’s Jillian Keczkemethy as 2026 ELITE 100 Patient Experience Architect
INDIANAPOLIS, May 13, 2026 /PRNewswire/ — Momentum Life Sciences proudly announces that Jillian Keczkemethy, Director of Client Solutions, has been selected for the prestigious 2026 ELITE 100 by PM360 in the Patient Experience Architect category for her exceptional contributions to patient support and engagement. Keczkemethy has distinguished herself by pairing data-driven decision-making with a relentless focus
-
Curefundr Launches First Crowdfunding Platform Dedicated to Cancer Research
LOS ANGELES, May 11, 2026 /PRNewswire/ — Curefundr has debuted as the first fintech-driven crowdfunding platform built exclusively to bypass the bureaucratic bottlenecks of oncology research. By creating a direct pipeline between global donors and top-tier labs, the platform is designed to eliminate the “funding gap” that frequently stalls breakthrough medical studies before they can reach clinical
-
Landmark CLiMB Study Demonstrates Superior Sensitivity of HelioLiver™, a Multi-Analyte Blood Test, Over Ultrasound for Early Detection of Hepatocellular Carcinoma
Prospective multicenter trial shows HelioLiver™ detects more, early hepatocellular carcinoma than abdominal ultrasound for high-risk patients with cirrhosis IRVINE, Calif., May 6, 2026 /PRNewswire/ — Helio Genomics, an AI-powered TechBio company focused on early cancer detection, today announced the publication of a study in the Journal of Hepatology demonstrating the performance of HelioLiver™, its multi-analyte noninvasive
-
Prevounce Health Analysis Finds Remote Patient Monitoring Delivers Significant, Sustained Blood Pressure Reductions
INDIANAPOLIS, May 6, 2026 /PRNewswire/ — Prevounce Health, a leading provider of connected care management and remote patient monitoring (RPM) solutions, today released findings from a retrospective cohort analysis of hypertensive patients. The study found that an RPM program, combined with structured virtual care management, produced significant and sustained blood pressure (BP) reductions across a
-
Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility
Recent Milestones Aim to Bring a New Category of Care to One of Veterinary Medicine’s Largest Unmet Needs Gallant granted eligibility for expanded conditional approval by FDA-CVM for canine osteoarthritis (OA) stem cell therapy; targeting conditional approval in 2028. Randomized, blinded, placebo-controlled pilot study shows statistically significant improvement in Gallant’s uterine-derived mesenchymal stromal cell (UMSC)
-
Coral Gables Hospital CEO Natalie Rodriguez Emerges as a Leading Voice in Healthcare and Community Leadership
CORAL GABLES, Fla., May 6, 2026 /PRNewswire/ — Coral Gables Hospital highlights the impactful start of Chief Executive Officer Natalie Rodriguez, whose leadership is already resonating across the City Beautiful through visibility, engagement, and a clear vision for the future. Coral Gables Hospital’s Earth Day Celebration, themed “Growing Today for a Greener Tomorrow.” Fifth Annual
